GlassScriptPhysician profile
Jairo D Libreros
NPI 1518922285
$2,182.65
in general payments reported to CMS, 2019-2025
25 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $428 · 2021: $823 · 2022: $202 · 2023: $221 · 2024: $21.77 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $535.88 | 2020-2021 | |
| Abbvie INC. | $431.05 | 2021-2025 | |
| Allergan, INC. | $217.66 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $179.33 | 2019-2022 | |
| Pfizer INC. | $117.41 | 2023-2025 | |
| Ge Healthcare | $91.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.90 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $67.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.17 | 2019 | |
| Supernus Pharmaceuticals, INC. | $48.78 | 2019-2021 | |
| Lilly USA, LLC | $45.75 | 2019-2022 | |
| Biogen, INC. | $40.49 | 2023 | Spinraza |
| Nevro Corp. | $36.90 | 2023 | Senza |
| Zyla Life Sciences, INC. | $36.75 | 2020 | |
| Biodelivery Sciences International, INC. | $28.90 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $23.92 | 2025 | Roxybond |
| Almatica Pharma LLC | $22.01 | 2021 | |
| Hikma Pharmaceuticals USA | $19.25 | 2022 | |
| Amarin Pharma, INC. | $19.19 | 2020 | |
| Electronic Waveform Lab, INC. | $17.82 | 2020 | |
| Upsher-Smith Laboratories LLC | $16.98 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.60 | 2019 | |
| Horizon Therapeutics Plc | $16.49 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Libreros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.